Arecor Therapeutics PLC (6UI) Price & Analysis

0 Followers

6UI Stock Chart & Stats

€0.82

>-€0.01(-0.58%)

At close: Jan 08 4:00 PM EST

€0.82

>-€0.01(-0.58%)

Day’s Range― - ―

52-Week Range€0.48 - €1.01

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€29.07M

Enterprise Value€14.71

Total Cash (Recent Filing)€6.13M

Total Debt (Recent Filing)€98.00K

Price to Earnings (P/E)38.9

Beta-0.05

Next Earnings

Sep 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.02

Shares Outstanding37,756,600

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.43

Price to Book (P/B)4.71

Price to Sales (P/S)17.73

P/FCF Ratio-12.72

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)€10.25K

Bulls Say, Bears Say

Bulls Say

Reusable Formulation PlatformArestat targets improved stability and usability of established biologics, giving Arecor a reusable platform across insulin and other therapeutic areas. This can support multiple partnering opportunities without relying on a single product.

Very Low LeverageMinimal debt limits interest obligations and reduces balance-sheet risk while Arecor funds development. This provides greater financial flexibility than a highly levered biotech, although it does not eliminate the need for future funding.

Improving Cash-burn TrendThe substantial reduction in free-cash-flow outflow indicates progress in controlling cash consumption. If sustained, this could extend the runway and improve negotiating flexibility with partners, despite the business remaining non-self-funding.

Bears Say

Sharp Revenue DeclineThe abrupt reversal from prior revenue growth highlights material volatility in a partnership- and milestone-driven model. Such uneven income makes planning difficult and increases dependence on successfully securing new collaborations or commercial milestones.

Persistent Operating LossesRecurring negative EBIT and EBITDA show that the core operations have not yet reached economic scale. Continued development spending without operating profitability could constrain reinvestment capacity and leave results dependent on non-operating items.

Ongoing Funding DependencePersistent cash burn means Arecor remains reliant on financing, grants, or partnering receipts to support operations. Declining equity alongside sustained losses raises the risk of future dilution or reduced investment if external funding becomes less available.

Arecor Therapeutics PLC News

Arecor’s AT278 Data Published, Underscoring Ultra-Rapid Potential in High-Dose Diabetes Care

The latest update is out from Arecor Therapeutics PLC ( ($GB:AREC) ). Arecor Therapeutics announced that full clinical...

15d ago

Arecor AGM Resolutions Pass Amid Shareholder Dissent Over Director Re-Election

Arecor Therapeutics PLC ( ($GB:AREC) ) just unveiled an update. Arecor Therapeutics reported that all resolutions were approved...

3M ago

Arecor Grants Performance-Linked Share Options to Senior Management

An announcement from Arecor Therapeutics PLC ( ($GB:AREC) ) is now available. Arecor Therapeutics has granted 455,000 options...

3M ago

Arecor Targets Partnering Opportunities at Major Diabetes and Biotech Conferences

Arecor Therapeutics PLC ( ($GB:AREC) ) has provided an update. Arecor Therapeutics will showcase its emerging diabetes and...

3M ago

Arecor Posts 2025 Annual Report and Sets Hybrid-Access AGM

An update from Arecor Therapeutics PLC ( ($GB:AREC) ) is now available. Arecor Therapeutics has released its Annual...

4M ago

Arecor boosts cash and partnerships as AT278 insulin heads toward Phase 2

Arecor Therapeutics PLC ( ($GB:AREC) ) has provided an announcement. Arecor Therapeutics reported audited full-year 2025 results highlighting...

5M ago

Arecor sets April date for FY25 results as it advances ultra-rapid insulin and oral peptide platform

Arecor Therapeutics PLC ( ($GB:AREC) ) just unveiled an announcement. Arecor Therapeutics plc, a Cambridge-based clinical-stage biotech listed...

5M ago

Arecor Secures First Ligand Milestone to Advance Lead Insulin Program

Arecor Therapeutics PLC ( ($GB:AREC) ) has issued an update. Arecor Therapeutics has received its first $0.5 million...

5M ago

Arecor to Spotlight Ultra-Concentrated Insulin AT278 at Key Diabetes and MedTech Conferences

Arecor Therapeutics PLC ( ($GB:AREC) ) has provided an announcement. Arecor Therapeutics will showcase its lead diabetes programme...

6M ago

Arecor sharpens diabetes focus as AT278 and oral peptide platform advance

The latest update is out from Arecor Therapeutics PLC ( ($GB:AREC) ). Arecor Therapeutics has sharpened its strategy...

7M ago

6UI FAQ

What was Arecor Therapeutics PLC’s price range in the past 12 months?

Arecor Therapeutics PLC lowest stock price was €0.48 and its highest was €1.01 in the past 12 months.

What is Arecor Therapeutics PLC’s market cap?

Arecor Therapeutics PLC’s market cap is €29.07M.

When is Arecor Therapeutics PLC’s upcoming earnings report date?

Arecor Therapeutics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 27 days.

How were Arecor Therapeutics PLC’s earnings last quarter?

Currently, no data Available

Is Arecor Therapeutics PLC overvalued?

According to Wall Street analysts Arecor Therapeutics PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arecor Therapeutics PLC pay dividends?

Arecor Therapeutics PLC does not currently pay dividends.

What is Arecor Therapeutics PLC’s EPS estimate?

Arecor Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arecor Therapeutics PLC have?

Arecor Therapeutics PLC has 37,756,600 shares outstanding.

What happened to Arecor Therapeutics PLC’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Arecor Therapeutics PLC?

Currently, no hedge funds are holding shares in DE:6UI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Arecor Therapeutics PLC

Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.